[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-related-pain\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-related-pain":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,90,112,135],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100637464","efficacy-of-spinal-cord-stimulation-in-chemotherapy-induced-peripheral-neuropathy-100637464",false,"NCT07579611","Efficacy of Spinal Cord Stimulation in Chemotherapy-Induced Peripheral Neuropathy","Efficacy of Posterior Spinal Cord Stimulation in Chemotherapy-Induced Peripheral Neuropathic Pain: A Multicenter Randomized Crossover Trial","CHEMOSTIM","Inclusion Criteria:\n\n1. Adult patient with chemotherapy-induced painful neuropathy (platinum salts, vincristine, taxanes, alkaloids, epothilone, thalidomide, etc.) evolving for at least 1 year\n2. Indication for spinal cord stimulation validated by a multidisciplinary team meeting according to SFETD\u002FSFNM guidelines\n3. Resistance to pharmacological or topical treatment (failure of at least two therapeutic lines or intolerable side effects: anticonvulsants, antidepressants, capsaicin, etc.)\n4. Pain score \\> 5\u002F10 on numerical scale in the lower limbs\n5. Patient able to understand and give informed consent to the protocol\n6. Patient affiliated to the French Social Security system\n7. Patient able to complete follow-up questionnaires\n\nExclusion Criteria:\n\n* 1\\. Contraindication to spinal cord stimulation:\n* Extensive laminectomy\n* Coagulopathy\n* Intercurrent infections\n* Psychiatric disorders\n\n  2\\. Body Mass Index (BMI) \\> 40\n\n  3\\. Life expectancy \\\u003C 1 year\n\n  4\\. Ongoing pregnancy\n\n  5\\. Patient under guardianship or curatorship\n\n  6\\. Patient already implanted with a spinal cord stimulation device","ALL","18 Years","100 Years",{"count":21,"type":22},68,"ESTIMATED","INTERVENTIONAL",[25],"NA","Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent and debilitating side effect of many cancer treatments. It affects 28 to 48% of patients receiving chemotherapy. Symptoms include tingling, numbness, burning sensations, and pain mainly in the hands and feet. While CIPN often improves after chemotherapy ends, in some patients the pain persists and becomes chronic, severely impairing quality of life, sleep, and daily functioning.\n\nCurrently, no treatment has been shown to prevent CIPN. For patients with chronic pain, duloxetine is the only recommended drug, but its efficacy is limited. When standard medications fail, patients have very few options.\n\nSpinal cord stimulation (SCS) is a well-established neurosurgical technique used to treat various forms of chronic neuropathic pain, including pain after surgery, trauma, or diabetes. In this procedure, thin electrodes are placed in the epidural space near the spinal cord and connected to a small implantable pulse generator. The electrical impulses delivered by the device modulate pain signals in the nervous system.\n\nPreliminary case reports suggest that SCS may be effective in patients with CIPN, but no randomized controlled trial has yet established its value in this specific indication. The CHEMOSTIM study aims to fill this gap.\n\nCHEMOSTIM is a multicenter, prospective, randomized crossover trial. All enrolled patients will undergo SCS implantation. Participants will then be randomized to receive either active stimulation first followed by sham stimulation, or sham stimulation first followed by active stimulation. In the sham phase, the device is implanted but switched off following a simulated programming session, so patients cannot tell which phase they are in.\n\nThe primary outcome is the proportion of patients achieving more than 50% pain reduction on a Visual Analog Scale (VAS) during the active stimulation phase compared to the sham stimulation phase, assessed at 4 months.\n\nSecondary outcomes include changes in quality of life, anxiety and depression, sleep quality, medication use, individualized goal attainment, neurological examination, and nerve conduction studies. The study will also evaluate post-stimulation effects and complications.\n\nEligible patients are adults with chronic CIPN evolving for at least one year, with pain greater than 5\u002F10 in the lower limbs, who have failed at least two lines of pharmacological treatment (antidepressants, anticonvulsants, topical agents, etc.) and whose indication for SCS has been validated by a multidisciplinary team following SFETD\u002FSFNM guidelines.",[28,29,30],"Neuropathic Pain","Chemotherapy-induced Peripheral Neuropathy (CIPN)","Cancer-related Pain",[32,33,34,35],"spinal cord stimulation","posterior cord stimulation","neuropathic pain","Chemotherapy-induced neuropathy","NOT_YET_RECRUITING","2026-05-06",{"date":39,"type":40},"2026-05-12","ACTUAL",{"date":42,"type":22},"2026-09-01",{"date":44,"type":22},"2029-05-01",{"name":46,"class":47},"Assistance Publique Hopitaux De Marseille","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":59,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":71,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":48},"100613134","developing-a-multimodal-cancer-pain-database-to-support-ai-based-automatic-pain-assessment-100613134","NCT07262632","Developing a Multimodal Cancer Pain Database to Support AI-Based Automatic Pain Assessment","SENSAI: Seeing, hEaring, seNsing: Smart, Effortless and Objective Pain Assessment With Mobile AI Technology - DataBase Development","SENSAI-DBD","Inclusion Criteria:\n\n* Adult patients (≥18 years)\n* Diagnosed with cancer, active\n* Able to communicate verbally in Dutch or English\n* Able to provide written informed consent.\n* Pain group specific:\n* Experiencing pain related to cancer\n* Admitted to the hospital due to pain\n* Control group specific:\n* Not experiencing pain (NRS = 0)\n* Admitted to the hospital for chemotherapy\n\nExclusion Criteria:\n\n* Cognitive, physical, or medical limitations that prevent participation in the audiovisual recording sessions or affect facial expressions or voice (e.g. facial paralysis, tracheostomy, severe speech impairment).\n* Critical illness or end-of-life care where participation would impose an additional burden.\n* Experiencing pain not associated with cancer\n* Infectious isolation precautions that prevent safe data collection",{"count":58,"type":22},200,"3 Weeks","OBSERVATIONAL","The goal of this observational study is to collect short video and sound recordings of people with cancer to create a secure database that can be used in future research to develop an artificial intelligence (AI) tool for pain assessment. The main aim is to build a large, high-quality collection of audiovisual data showing how people with cancer express themselves when they do and do not have pain.\n\nParticipants will include adults with cancer who are admitted to the oncology ward for pain treatment and a control group admitted for chemotherapy who have no pain. After giving consent, participants will:\n\n* Be recorded on video (from the shoulders up) for up to 60 seconds while reading a short sentence and describing their pain or daily experience.\n* Complete a short questionnaire about their mood and pain expression.\n* Allow researchers to collect some information from their medical record, such as their pain score, medications, and cancer type.\n\nThese recordings will be securely stored and used to create a database for future AI research. No medical tests, new treatments, or extra hospital visits are involved. This study will provide the foundation for developing future AI-based tools that could support doctors and patients in monitoring and managing pain more accurately and easily.",[30,63,64,65,66,67,68,69,70],"Pain Assessment","Artificial Intelligence (AI)","Oncology","Oncology Pain","Database","Facial Expression","Voice","Cancer",[30,72,64,65,66,67,73,74,75,76,77,78,79],"Pain assessment","Facial Action Unit","Vocalizations","Acoustic","Automatic assessment","Machine learning","Audiovisual data","Paralinguistics","RECRUITING","2026-03-10",{"date":83,"type":40},"2026-03-11",{"date":85,"type":40},"2025-12-01",{"date":87,"type":22},"2027-12-31",{"name":89,"class":47},"Dr. Mark Mulder",{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":4,"eligibilityCriteria":96,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":97,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":48},"100618016","a-prospective-observational-study-of-first-line-systemic-therapy-combined-with-celiac-plexus-blockade-for-advanced-biliopancreatic-cancer-with-pain-100618016","NCT07326137","A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade for Advanced Biliopancreatic Cancer With Pain","A Prospective Observational Study of First-Line Systemic Therapy Combined With Celiac Plexus Blockade in Patients With Advanced Biliopancreatic Malignancies and Cancer-Related Pain","Inclusion Criteria:\n\n* Histologically confirmed advanced biliopancreatic malignancy (including biliary tract cancer or pancreatic cancer).\n* Cancer-related pain: Baseline Numeric Rating Scale (NRS) pain score ≥ 4 points for over 1 week, with plans to receive celiac plexus neurolysis (CPN).\n* Scheduled to receive a first-line systemic treatment regimen (e.g., PD-1\u002FPD-L1 inhibitor monotherapy or in combination with chemotherapy\u002Ftargeted therapy).\n* ECOG Performance Status of 0-2 and an estimated life expectancy of ≥ 3 months.\n\nExclusion Criteria:\n\n* Previous history of celiac plexus neurolysis or ablation.\n* Coagulation disorders (INR \\> 1.5, platelet count \\\u003C 50 × 10⁹\u002FL).\n* Severe cardiac, hepatic, or renal insufficiency (Child-Pugh Class C, estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin, NYHA Class III-IV heart failure).\n* Contraindications to celiac plexus block (e.g., local infection, anatomical variation).\n* Any other condition that, in the investigator's judgment, would preclude safe participation in the study.",{"count":98,"type":22},103,"This study is for patients with advanced bile duct or pancreatic cancer who are experiencing pain from their disease. The purpose of this research is to learn about the effects of combining a standard pain relief treatment (Celiac Plexus Block) with standard first-line cancer drugs.\n\nPatients in this study will receive the Celiac Plexus Block procedure, which is intended to reduce pain, and will then begin their standard cancer medication regimen. Researchers will observe and compare how well this combined approach works to control pain and the cancer itself, and will monitor for any side effects. Participation in this study involves being followed by the research team for up to 2 years to track health outcomes.\n\nThe goal is to see if starting cancer treatment together with this specialized pain management technique is more helpful for patients compared to what is already known about the standard treatments alone.",[101,102,30],"Advanced Biliary Tract Cancer(BTC)","Advanced Pancreatic Cancers","2026-02-10",{"date":105,"type":40},"2026-02-11",{"date":107,"type":40},"2025-12-26",{"date":109,"type":22},"2028-12-26",{"name":111,"class":47},"Tongji Hospital",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":119,"targetDuration":4,"studyType":23,"phases":121,"briefSummary":122,"conditions":123,"keywords":4,"overallStatus":80,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":134},"100570303","trauma-informed-procedural-pain-intervention-refinement-of-an-evidence-based-protocol-100570303","NCT06705491","Trauma-Informed Procedural Pain Intervention: Refinement of an Evidence-Based Protocol","TIPPI-R","Inclusion Criteria:\n\n* Patient is receiving treatment at Norton Children's Cancer Institute, Norton Children's Hospital, University of Kentucky Children's Hospital or DanceBlue Clinic.\n* Patient has been diagnosed with an oncology diagnosis.\n* Patient and family are English-speaking.\n* Patient is between the ages 0-18.\n\nExclusion Criteria:\n\n* Families not proficient in English.\n* Patient is 19 years or older.\n* Patient is not receiving treatment at Norton Children's Cancer Institute, Norton Children's Hospital, University of Kentucky Children's Hospital or DanceBlue Clinic.\n* Patient does not have an oncology diagnosis.\n* Patient and family have any CPS involvement.",{"count":120,"type":22},100,[25],"The Trauma-Informed Procedural Pain Intervention (TIPPI-R) has been developed as a standardized way to provide education and teach evidence-based strategies for managing pain and distress that may occur during pediatric cancer treatment. The purpose of this clinical trial study is to test how helpful TIPPI-R is in supporting children and families manage pain and distress during the initial stages of cancer treatment. The main questions this study aims to answer are:\n\n* Does TIPPI-R increase use of helpful pain coping strategies for pediatric cancer patients?\n* Does TIPPI-R help lower perceived pain intensity during initial stages of cancer treatment?\n* Does TIPPI-R increase patient and family confidence in coping with pain and distress during cancer treatment?\n\nResearchers will compare pain experiences and use of pain coping strategies for families who receive the TIPPI-R intervention and families who receive standard of care to see if TIPPI-R decrease pain and distress during the initial stages of cancer treatment.\n\nParticipants will:\n\n* Complete surveys to measure pain and distress within 5 weeks of initial diagnosis (Time 1)\n* Either receive the TIPPI-R intervention or standard of care\n* Complete surveys to measure pain and distress 4 weeks after initial consent or TIPPI-R intervention delivery (Time 2)",[124,30],"Procedural Pain","2026-01-28",{"date":127,"type":40},"2026-01-30",{"date":129,"type":40},"2025-02-07",{"date":131,"type":22},"2026-12",{"name":133,"class":47},"University of Louisville",4,{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":23,"phases":145,"briefSummary":146,"conditions":147,"keywords":155,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":171,"leadSponsor":172,"locationsCount":48},"100591303","neurolytic-block-techniques-in-abdominal-visceral-cancer-pain-100591303","NCT06978673","Neurolytic Block Techniques In Abdominal Visceral Cancer Pain","Comparison of Neurolytic Block Techniques for the Treatment of Abdominal Visceral Pain and Their Influence On The Quality of Life of Patients With Cancer","CONCERN","Inclusion Criteria:\n\nPatients aged 18 years or older Presence of localized visceral pain in the upper abdomen originating from cancer of the stomach, duodenum, distal esophagus, ascending or transverse colon, liver, biliary tract, or pancreas\n\nIneffectiveness of analgesic treatment with third-step opioids according to the WHO analgesic ladder, including:\n\nOpioids (≥ 60 mg\u002Fday of morphine equivalents) Antidepressants (tricyclic or dual-action), at any dosage Gabapentinoids, at any dosage Presence of side effects from analgesics that are difficult to manage with medication\n\nExclusion Criteria:\n\nPresence of ascites Presence of deep vein thrombosis Presence of hepatic failure: Child-Pugh class B or C Presence of renal failure: estimated glomerular filtration rate (eGFR) \\\u003C 60 ml\u002Fmin\u002F1.73 m² Use of any anticoagulant medication\n\nClinical coagulation disorder, defined as:\n\nINR \\> 1.5 Prothrombin activity \\\u003C 70% or prothrombin time \\> 13.5 seconds aPTT \\> 40 seconds Cardiovascular failure: NYHA class III",{"count":144,"type":22},64,[25],"The neurolytic blocks of sympathetic chains are commonly used for the treatment of cancer-related pain. This study aims to compare celiac plexus neurolysis and splanchnic nerve neurolysis for the treatment of abdominal visceral pain and its influence on the quality of life of patients with cancer.",[148,149,150,151,30,152,153,154],"Cancer, Malignant Tumors","Abdominal Cancer","Cancer Pain","Visceral Pain","Pain Management","Celiac Ganglia","Sympathetic Ganglia",[156,157,158,159,160,161,162,163,164,165,166],"cancer pain","visceral pain","abdominal cancer","cancer","abdominal pain","cancer-related pain","pain management","neurolytic block","splanchnic nerve block","celiac plexus block","sympathetic neurolysis","2025-05-30",{"date":169,"type":40},"2025-06-03",{"date":167,"type":22},{"date":131,"type":22},{"name":173,"class":47},"Instituto do Cancer do Estado de São Paulo"]